In this context, the treatment-associated acquisition of ESR1 mutations, which presents a major therapeutic challenge with current approved hormonal agents, may in fact serve to predict continued cancer dependence on ER activity and hence susceptibility to FDA-approved elacestrant, independent of prior fulvestrant therapy. The gene discussed is ESR1; the disease is cancer.